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Abstract
Background: Interferon-gamma (IFN-γ) release assays (IGRAs) were designed to detect latent
tuberculosis infection (LTBI). However, discrepancies were found between the tuberculin skin test
(TST) and IGRAs results that cannot be attributed to prior Bacille Calmètte Guerin vaccinations.
The aim of this study was to evaluate tools for improving LTBI diagnosis by analyzing the IFN-γ
response to RD1 proteins in prolonged (long-term response) whole blood tests in those subjects
resulting negative to assays such as QuantiFERON-TB Gold In tube (QFT-IT).
Methods: The study population included 106 healthy TST+ individuals with suspected LTBI (recent
contact of smear-positive TB and homeless) consecutively enrolled. As controls, 13 healthy
subjects unexposed to M. tuberculosis (TST-, QFT-IT-) and 29 subjects with cured pulmonary TB
were enrolled. IFN-γ whole blood response to RD1 proteins and QFT-IT were evaluated at day 1
post-culture. A prolonged test evaluating long-term IFN-γ response (7-day) to RD1 proteins in
diluted whole blood was performed.
Results: Among the enrolled TST+ subjects with suspected LTBI, 70/106 (66.0%) responded to
QFT-IT and 64/106 (60.3%) to RD1 proteins at day 1. To evaluate whether a prolonged test could
improve the detection of LTBI, we set up the test using cured TB patients (with a microbiologically
diagnosed past pulmonary disease) who resulted QFT-IT-negative and healthy controls as
comparator groups. Using this assay, a statistically significant difference was found between IFN-γ
levels in cured TB patients compared to healthy controls (p < 0.006). Based on these data, we
constructed a receiver operating characteristic (ROC) curve and we calculated a cut-off. Based on
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BMC Infectious Diseases 2009, 9:182 http://www.biomedcentral.com/1471-2334/9/182the cut-off value, we found that among the 36 enrolled TST+ subjects with suspected LTBI not
responding to QFT-IT, a long term response to RD1 proteins was detected in 11 subjects (30.6%).
Conclusion: These results indicate that IFN-γ long-term response to M. tuberculosis RD1 antigens
may be used to detect past infection with M. tuberculosis and may help to identify additional
individuals with LTBI who resulted negative in the short-term tests. These data may provide useful
information for improving immunodiagnostic tests for tuberculosis infection, especially in
individuals at high risk for active TB.
Background
In recent years, several immunodiagnostic assays have
been developed for diagnosing Mycobacterium tuberculosis
(M. tuberculosis) infection [1,2]. These assays, referred as
interferon (IFN)-γ release assays (IGRAs), have been spe-
cifically designed to overcome the problem of low specif-
icity of the tuberculin skin test (TST). In fact, they detect
cellular immune response to antigens which are absent in
Bacille Calmètte Guerin (BCG) and most environmental
mycobacteria, and specifically present in M. tuberculosis.
Two such antigens, early-secreted antigenic target (ESAT)-
6 and culture filtrate protein (CFP)-10, encoded in the
mycobacterial genomic region of difference (RD)-1 were
first evaluated in a 6-day lymphocyte stimulation test
(LST) and found to be sensitive and specific for diagnos-
ing tuberculosis (TB) [3-7]. Subsequently, other IGRAs
were developed that differed from the classical LST with
respect to the in vitro incubation period, the type of cells
cultured [whole blood, frozen or fresh peripheral blood
mononuclear cells (PBMC)] and the way that the IFN-γ
response is detected [(by enzyme-linked immunosorbent
assay (ELISA) or enzyme-linked immunospot assay (ELIS-
POT)].
A number of clinical studies found discrepancies between
TST and IGRAs that were mostly attributed to TST positiv-
ity associated with prior BCG vaccination [8-10]. How-
ever, data from recent studies [11-13] indicate that this
explanation may not account for all discrepant results, as
a substantial group of BCG-unvaccinated subjects with
TST indurations of >15 mm had negative results by com-
mercially available IGRAs, the QuantiFERON-TB Gold In-
tube (QFT-IT) test and/or the T-SPOT. TB test (Oxford
Immunotec, Abingdon, United Kingdom) [11-13]. These
data suggest that IGRAs may have a suboptimal sensitiv-
ity, and indicate the need to develop new tools to increase
their accuracy.
Prolonged whole blood stimulation has been used to
detect memory response in vaccine trials [14]. Using RD1
proteins, it has also been employed to identify subjects
with LTBI comparing the results obtained with those
found by short-term ELISPOT [15].
The aim of this study was to evaluate if IFN-γ response to
RD1 antigens by prolonged (long-term response, 7-day)
whole blood stimulation could improve identification of
LTBI in subjects resulting negative to QFT-IT. The study
population included 106 healthy Human Immunode-
fciency Vius (HIV)-negative TST+ individuals exposed to
M. tuberculosis (recent contacts of smear positive pulmo-
nary TB patients) or at higher likelihood to have LTBI,
such as the homeless population, as they are at higher risk
to develop active TB disease compared to the general pop-
ulation [16]. Controls included 13 TST- QFT-IT-unexposed
individuals and 29 cured TB subjects. All the subjects were
consecutively enrolled.
Methods
Study population
At the "L. Spallanzani" National Institute for Infectious
Diseases (INMI) we consecutively enrolled in this study
TST+ individuals with risk factors for TB infection includ-
ing close contacts in the last 3 months of patients with a
positive sputum culture for M. tuberculosis and a group of
TST+ homeless people known to have been exposed to M.
tuberculosis in the past. Chemoprophylaxis was offered to
all subjects, thereafter referred to as suspected LTBI, but
none of them was under chemoprophylaxis at the time of
the study. As control groups, we enrolled: 1) "controls",
individuals with no risk of M. tuberculosis infection who
tested TST-negative and QFT-IT-negative; 2) "cured tuber-
culosis", individuals with culture-positive pulmonary
tuberculosis at the time of diagnosis and who were cul-
ture-negative upon treatment completion when the draw
blood was performed.
Individuals who tested positive to HIV-antibody assay or
who were on immunosuppressive drugs were not
included in the study. Upon enrolment, demographic and
epidemiological information was collected by a physician
through a structured questionnaire, including informa-
tion about BCG vaccination.
The study was approved by the INMI ethical committee,
and all enrolled individuals provided written consent.Page 2 of 8
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Participants underwent a TST on the day of blood sam-
pling (see below). The TST was administered by the Man-
toux procedure using 5 IU of tuberculin (Chiron, Siena,
Italy). Results were read after 72 hrs. Induration of at least
5 mm was considered a positive response for the group of
close contacts and a reaction of ≥ 10 mm was considered
positive for homeless people and controls [17].
Commercially available IGRA
QuantiFERON TB-Gold In tube (Cellestis Limited) was
used. The tube containing TB antigen uses overlapping
peptides from CFP-10 and ESAT-6 [18] and TB7.7. The
assay was performed and the results were scored as indi-
cated by the manufacturer (cut-off value for a positive test
was 0.35 IU/ml). For IFN-γ values above 10 IU/ml serial
dilutions of plasma were performed.
Whole blood cultures with M. tuberculosis antigens and 
mitogen
1-day (short-term) response
0.5 ml per well of heparinized whole blood was seeded in
a 48-well plate (Corning Costar, Corning Incorporated,
New York, NY, USA) and treated with RD1 intact proteins
(ESAT-6 and CFP-10) at 0.2 μg/ml each protein (Lionex,
Braunschweig, Germany) and the mitogen phytohaemag-
glutinin (PHA) at 5 μg/ml (Sigma, St Louis, MO, USA).
Samples were incubated for 24 hrs. At day 1, plasma was
harvested and cold stored until tested (+4°C or if used
after 15 days at -20°C).
7-day (long-term) response
We used the described methodology [14,15]. Briefly at the
day of sampling, an aliquot of blood was diluted 5-fold
using RPMI 1640 supplemented with penicillin, strepto-
mycin and 2 mM L-glutamine (all four products are from
Euroclone Ltd, United Kingdom) and was plated into 48-
well plates (Corning) and stimulated as described above.
The day-7 diluted plasma was harvested following incuba-
tion at 37°C and cold stored until tested (+4°C or if used
after 15 days at -20°C).
IFN-γ determination
IFN-γ from day-1 and day-7 plasma were evaluated by a
commercial ELISA (CMI, Cellestis Limited, Carnegie, Vic-
toria, Australia) and are presented as IU/ml after subtrac-
tion of the appropriate control. For day-1 analysis, a cut-
off value was previously determined by constructing a
Receiver Operator Characteristic (ROC) curve by means of
LABROC-1 software and was 0.7 IU/mL for all stimuli
[19,20]
Statistical analysis
The main outcome of the study was the evaluation of IFN-
γ production in response to the mitogen PHA and anti-
genic stimulation in the QFT-IT and whole blood assays
(WBA), expressed as dichotomous (positive/negative)
and continuous (IU/ml) measures. Median and inter-
quirtile range (IQR) of IFN-γ production were calculated.
The Mann-Whitney U test was used to compare continu-
ous variables and Chi square or McNemar tests were used
for categorical variables. The cut-off value for definition of
positivity of the WBA based on RD1 proteins at day 7 was
defined by ROC analysis. SPSS v 14 for Windows (SPSS
Italia srl, Bologna, Italy) and Prism 4 software (Graphpad
Software 4.0, San Diego, CA, USA) were used in the anal-
ysis.
Results
Characteristics of the population
We studied a population of TST+ subjects with risk factors
for LTBI, 54 healthy contacts of patients with a positive
pulmonary TB smear and 52 homeless people. No differ-
ences were found in terms of the characteristics reported
and therefore the data were pooled together. The popula-
tion is referred to as suspected LTBI. As controls, we used
cured TB subjects and healthy individuals unexposed to
M. tuberculosis who resulted negative to TST and QFT-IT.
The characteristics of the groups are reported in table 1.
Note that among the suspected LTBI subjects, the TST
median was high (20 mm).
Responses to QFT-IT and RD1 proteins by short-term 
stimulation
All the enrolled subjects responded to PHA (data not
shown). As for the selection performed, none of the con-
trols responded to the QFT-IT and to RD1 proteins. The
median of IFN-γ production in response to QFT-IT was 0
IU/mL (IQR: 0-0) and to RD1 proteins 0 IU/mL (IQR: 0-
0.1).
Among the enrolled TST+ subjects with suspected LTBI, the
response to QFT-IT was found in 66.0% (70/106),
whereas to RD1 proteins in 60.3% (64/106) (table 2).
Among all of the subjects of this group, the median of
IFN-γ production in response to QFT-IT was 2.3 IU/mL
(IQR: 0-15.1) and to RD1 proteins 1.4 IU/mL (IQR: 0.2-
8.9). Among the responders, the median of IFN-γ produc-
tion in response to QFT-IT was 8.1 IU/mL (IQR: 2.4-22.6)
and to RD1 proteins 7.6 IU/mL (IQR: 2.3-20.3).
Among the cured TB subjects, the response to QFT-IT and
RD1 proteins was found for both tests in 65.5% (19/29).
The median of IFN-γ production in response to QFT-IT
was 1.1 IU/mL (IQR: 0.1-4.2) and to RD1 proteins 1.6 IU/
mL (IQR: 0.4-2.9). Among the responders, the median of
IFN-γ production in response to QFT-IT was 3.8 IU/mL
(IQR: 1.5-5.0) and to RD1 proteins 2.6 IU/mL (IQR: 1.6-
6.2).Page 3 of 8
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subjects with suspected LTBI and cured TB in response to
QFT-IT and RD1 proteins, in terms of both qualitative and
quantitative response (p > 0.05). However, a significant
statistical difference was found between controls and both
groups of suspected LTBI and cured TB in response to
QFT-IT and RD1 proteins, in terms of both qualitative and
quantitative response (p < 0.0001 for all comparisons).
Long-term response to RD1 proteins
In an effort to find new tools for detecting RD1-specific
response in those resulting negative to QFT-IT and to RD1
proteins at day-1 post stimulation, we evaluated long-
term-specific IFN-γ production. We used the RD1 proteins
as antigenic stimulus because previously used for pro-
longed WBA [15], because we could plate the diluted
blood and also because the results obtained by RD1 pro-
teins stimulation were similar to those obtained by QFT-
IT test, as reported above (Table 2) and in previous studies
[19,20].
As reported in the literature, IGRA scoring may become
negative after successful tuberculosis therapy in diseased
patients [21-23]. Therefore, we evaluated whether long-
term stimulation could be a good approach for detecting
a memory response in cured TB subjects at the time of
therapy completion that resulted negative to QFT-IT.
Within the 29 subjects with cured TB enrolled in the
study, 10 (34.4%) resulted QFT-IT-negative. In this sub-
group of subjects, the long-term IFN-γ response to RD1
Table 1: Characteristics of study subjects.
Controls
N (%)
13 (8.8)
TST+, suspected LTBI
N (%)
106 (71.6)
Cured TB
N (%)
29 (19.6)
Total
N (%)
148 (100)
Age Median (IQR) 33 (29.5-35) 35 (21-48) 31.5 (25-49) 36 (28-50)
Female Gender 8 (61.5) 33 (31.1) 15 (51.7) 56 (37.8)
Origin
Italy 12 (92.3) 49 (46.3) 9 (31.1) 70 (47.3)
Abroad 1 (7.7) 57 (53.7) 20 (68.9) 78 (52.7)
TST Median in mm (IQR) 0 (0) 20 (15-45) ND 20* (15-30)
TST+ 0 106 (100) ND 106/119** (89)
BCG
Vaccinated 4 (30.8) 37 (34.9) 19 (65.5) 60 (40.6)
unvaccinated
unknown
9 (69.2)
0
50 (47.2)
19 (17.9
10 (34.5)
0
69 (46.6)
19 (12.8)
Footnotes: BCG: Bacillus Calmètte et Guerin; LTBI: latent tuberculosis infection; N: number; TST: tuberculin skin test.
*among TST+
** among those tested by TST
Table 2: In vitro responses to M. tuberculosis antigens in the study group populations.
In vitro
response to:
Controls
N (%)
TST+, suspected LTBI
N (%)
Cured TB
N (%)
13 (100) 106 (100) 29 (100)
QFT-IT
Positive N.(%) 0 70 (66.03) 19 (63.3)
IFN-γ (IU/ml) median (IQR)
Among all
0 (0-0.1) 2.3 (0-15.1) 1.1 (0.1-4.2)
IFN-γ (IU/ml) median (IQR)
Among the positive responders
NA 8.1 (2.4-22.6) 3.8 (1.5-5.0)
RD1 proteins
Positive N.(%) 0 64 (60.3) 19 (65.5)
IFN-γ (IU/ml) median (IQR)
Among all
0 (0-0.2) 1.4 (0.2-8.9) 1.6 (0.4-2.9)
IFN-γ (IU/ml) median (IQR)
Among the positive responders
NA 7.6 (2.3-20.3) 2.6 (1.6-6.2)
Footnotes: IQR: inter quartile range; LTBI: latent tuberculosis infection; N: number; QFT-IT: QuantiFERON-TB Gold In-tube; RD: region of 
difference, TB: tuberculosis.Page 4 of 8
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IQR: 0.050-4.3) compared to healthy controls (median: 0;
IQR: 0-0.15) (Figure 1A). Based on these data, we per-
formed a ROC analysis using the QFT-IT-negative cured
TB subjects and the healthy controls as comparator groups
(Figure 1B). Significant results for area under the curve
(AUC) analysis were obtained [AUC, 0.84; confidence
interval (CI), 0.65-1.02, p < 0.005]. For scoring purposes
we chose a cut-off to maximize the sum of sensitivity and
specificity. We found that a cut-off of 0.75 (IU/ml) pre-
dicted a long term response in cured TB with 70.0% sen-
sitivity (95% CI, 34.75%-93.33%) and 100% specificity
(95% CI, 75.29%-100.0%).
Based on this cut-off value we scored the results as nega-
tive and positive. None of the controls resulted positive,
whereas among the cured TB subjects not responding to
QFT-IT, 7/10 (70%) scored positive (Figure 1A). Among
those with suspected LTBI who did not respond to QFT-IT
11/36 (30.6%) responded to the long-term test (Figure
1C). Moreover, in this subgroup, a higher, although not
significant level of IFN-γ production (p < 0.06) was found
in response to RD1 proteins (median: 0.1, IQR 0-1.65)
compared to controls.
We then evaluated the impact of BCG vaccination in the
response to the prolonged test in the suspected LTBI sub-
jects not responding to QFT-IT (Table 3). Among those
BCG-unvaccinated 5/14 (35.7%) responded to the pro-
longed test, among those BCG-vaccinated 3/15 (20.0%)
responded and among those with BCG status unknown 3/
7 (42.9%) responded. Based on these data, no clear asso-
ciation was found between BCG vaccination and lack of
response to the long-term test.
Discussion
In this study we demonstrated that IFN-γ long-term
response to M. tuberculosis RD1 proteins may be detected
in TST+ individuals who, although with a high likelihood
of having LTBI, resulted negative to a commercial IGRA.
Among these individuals, we found a specific-IFN-γ long-
term response in 11/36 (30.6%). A higher proportion of
positive responses (7/10, 70.0%) was found among
patients with cured TB, while no positive responses were
detected among low risk controls. These observations sug-
gest that an IFN-γ long-term response may indeed be asso-
ciated with TB infection. These results provide useful
information on the immunity against M. tuberculosis and
may be the preliminary basis for further improvement of
immunodiagnostic tests for LTBI. In particular it may be
A-B-C. Long-term response to RD1 proteins in cured TB subjects and suspect of LTBI resulted negative to QFT-IT compared to healthy cont olsFigure 1
A-B-C. Long-term response to RD1 proteins in cured TB subjects and suspect of LTBI resulted negative to 
QFT-IT compared to healthy controls. IFN-γ production in response to RD1 proteins was evaluated at day 7 in diluted 
whole blood of subjects who resulted QFT-IT-negative as described in the material and method section. A) IFN-γ release was 
significantly higher in cured TB patients than healthy controls (p < 0.006). Horizontal lines indicate the median IFN-γ produc-
tion. The data are presented as IU/mL. B). A ROC analysis was performed using the established cured TB group and the 
healthy controls group as comparator groups. C) IFN-γ production in response to RD1 proteins was higher, although not sig-
nificantly, compared to controls (p < 0.06). Eleven out of thirty-six (30.6%) responded to RD1 proteins. Horizontal lines indi-
cate the median IFN-γ production. The dotted line indicates the cut-off. The data are presented as IU/mL.Page 5 of 8
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with a "conventional IGRA" when a high sensitivity for
LTBI detection is required, such as in the screening of can-
didates for an immunosuppressive treatment.
In absence of a gold standard for diagnosing LTBI, identi-
fying a population of individuals with this condition is
not straightforward. However, we believe that the TST+
individuals enrolled in the present study were very likely
to have been infected with M. tuberculosis for two reasons:
first, they all had high risk factors for TB infection and sec-
ond, they had a great TST response which is most likely
associated to a past infection, even among those who are
BCG-vaccinated [24]. Thus, the observation that almost
34% of the these TST+ individuals had negative results by
QFT-IT may reflect, at least in part, a less than perfect sen-
sitivity to this test for detecting LTBI. This observation is
consistent with previous reports [10,15,25,26]. In particu-
lar, in two cross-sectional studies performed in South
Africa, approximately one-third of adults with a TST indu-
ration higher than 15 mm had a negative QFT-IT test
result and 38% had a negative T-SPOT.TB test result
[25,27]. Another study reported that in a mostly BCG-vac-
cinated Korean control population, 51% of the subjects
were TST+ and only 4% were QFT-IT positive, while the
expected prevalence of M. tuberculosis infection was 33%
[26].
We performed short and prolonged tests using identical
M. tuberculosis-specific proteins (RD1) that were found to
be highly specific for M. tuberculosis [1,2,11,25] to provide
consistent results. By this approach, one third of the TST+
individuals who had negative results by QFT-IT or RD1
proteins-based short-term assay resulted positive. Among
the participants who scored negative on short test, high
levels of IFN-γ could be detected by the prolonged test,
indicating that the observed discrepancy was not simply
explained by differences in the levels of detection of IFN-
γ. Another plausible explanation for the difference in sen-
sitivity would be the diversities in the in vitro incubation
periods for the QFT-IT and RD1 proteins-based short test
and prolonged assay. Probably the long term incubation
leads to higher likelihood of IFN-γ production since the
protein processing may be performed by a higher number
of T cell populations with various T-cell receptors types
with consequently a better antigen presentation than in
short term culture (1-day). Moreover, we hypothesize that
after 24 hours of incubation, only circulating effector
memory T-cells had sufficient time to produce IFN-γ,
while central memory T-cells or T cells in resting state first
started producing IFN-γ after a more prolonged incuba-
tion needed to allow them to differentiate. In individuals
who had been infected with M. tuberculosis in the past, the
number of circulating effector cells could be low, causing
negative results in a short-incubation assay but positive
responses after a prolonged incubation, as reported by our
studies and by others [11,28].
In accordance with this line of thought, findings from a
hepatitis C virus study show that short-term ELISPOT
responses were not influenced by depletion of lympho-
tropic chemokine receptor 7-positive T-cells, representing
memory cells, while the depletion of these memory cells
did decrease the antigen-specific responses after pro-
longed culture [29].
There is a lack of knowledge of the performance of IGRAs
with a short-term incubation period compared to those
with a more prolonged incubation time for detecting M.
tuberculosis infection. To our knowledge, there are few
studies comparing the overnight ELISPOT or WBA with
either the 6-day LST or the 7-day whole blood incubation
test and the results indicate that the prolonged tests per-
formed better [11,15,30]. This is also in agreement with
our previous data in which we reported that negative
responses to a panel of RD1 peptides in an overnight ELIS-
POT became positive responses in a cultured ELISPOT
[28].
In this study, 69.4% (25/36) of the enrolled TST+ subjects
with suspected LTBI who did not respond to QFT-IT, did
not respond to the long-term assay either. This was also
Table 3: Impact of BCG vaccination on the results obtained by the prolonged test.
TST+, suspected LTBI, not responding to QFT-IT
BCG
Response to the prolonged test Unvaccinated
N. 14 (%)
Vaccinated
N. 15 (%)
Unknown
N.7 (%)
Total
N. 36 (%)
No responders N. 25 9 (64.3) 12 (80.0) 4 (57.1) 25 (69.4)
Responders N. 11 5 (35.7) 3 (20.0) 3 (42.9) 11 (30.6)
Footnotes: BCG: Calmette et Guerin; LTBI: latent tuberculosis infection; N: number; QFT-IT: QuantiFERON TB-Gold-In tube; TST: tuberculin skin 
test.Page 6 of 8
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lower proportion (3/10, 30%). Further research is needed
to elucidate this lack of specific response.
This is a pilot study which presents limitations that will
require additional work to be overcome. Above all, the
study was performed on a relatively small number of indi-
viduals and certainly the research would benefit from a
larger study. Other limitations include the self-reported
BCG vaccination which may account for potential mis-
takes and imprecise information, the potential exposure
to environmental mycobacteria which may have caused a
cross-reaction with the tuberculin preparation present in
the TST and finally the amount of the refusal rate among
the homeless [refusal rate was 4.3% (13/300) at recruit-
ment, 10.1% (29/287) for the TST reading, and 11.8% (7/
59) to undergo further investigation for those resulted
TST+] that may have accounted for a selection of the sub-
jects tested.
Conclusion
In conclusion, IFN-γ long-term response to M. tuberculosis
specific antigens among TST+ individuals who resulted
negative to QFT-IT can potentially be considered to be an
additional tool for detecting LTBI. Further studies are
needed to confirm these data in a larger number of
patients and to evaluate the possible implications in terms
of TB risk, on the positivity of short vs. prolonged tests.
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